Document is current
Any future updates will be listed below
-
Authors
Wang, Sailan https://orcid.org/0000-0002-1269-0649
Nikamo, Pernilla
Laasonen, Leena
Gudbjornsson, Bjorn https://orcid.org/0000-0003-4631-6505
Ejstrup, Leif
Iversen, Lars https://orcid.org/0000-0003-1816-4508
Lindqvist, Ulla
Alm, Jessica J https://orcid.org/0000-0002-2066-9073
Eisfeldt, Jesper
Zheng, Xiaowei
Catrina, Sergiu-Bogdan https://orcid.org/0000-0002-6914-3902
Taylan, Fulya https://orcid.org/0000-0002-2907-0235
Vaz, Raquel
Ståhle, Mona https://orcid.org/0000-0002-3916-9343
Tapia-Paez, Isabel https://orcid.org/0000-0002-0535-4233
-
Funding
Funding for this research was provided by:
HudFonden (3378)
HudFonden (3227)
HudFonden (2808)
Reumatikerförbundet (R-968063)
Stiftelsen Konung Gustaf V:s 80-årsfond (FAI-2021-0819a)
psoriasisfonden
psoriasisfnden
European Academy of Dermatology and Venereology (PPRC-2022-40)
China Scholarship Council
Stiftelsen Sallsyntafonden
- License Information
-
More Information
Article History
Received: 14 June 2023
Revised: 19 January 2024
Accepted: 26 January 2024
First Online: 20 February 2024
Disclosure and competing interests statement
: LI has served as a consultant and/or paid speaker for and/or participated in clinical trials sponsored by: AbbVie, Almirall, Amgen, Astra Zeneca, BMS, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, Janssen Cilag, Kyowa, Leo Pharma, Micreos Human Health, MSD, Novartis, Pfizer, Regranion, Samsung, Union Therapeutics, UCB. The remaining authors declare no competing interests.
